Home
|
Contact us
|
Disclaimer
Corporate Overview
Management
Board of Directors
Contact us
Product pipeline
ELND005
Gastrin-based therapies
Anti-inflammation
Anti-glycemic compounds
Current partnership
In/Out-licensing opportunity
ELND005 Phase II
TT-223 Phase II
TT-223 + GLP-1 Phase Ib
Stock quote
Financial reports
Analyst coverage
Request information
Subscribe to e-mail alert
Press release 2010
Press release archive
Webcast and presentation
DRUG CANDIDATES
ELND005 - Alzheimer's disease
TT223 - diabetes
TT301/302 - inflammation
TT401/402 - diabetes
PRODUCT PIPELINE
View Transition's product pipeline
LATEST NEWS
Elan And Transition Therapeutics Announce Topline Summary Results Of Phase 2 Study and Plans for Phase 3 for ELND005 (Scyllo-inositol) - Aug 09, 2010
© 2010 Transition Therapeutics Inc.
